Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT03577665	TitleTerapia curativa con haz de protones para pacientes con metástasis hepática de cáncer colorrectal	Fase No aplicable	Date Added 2018-07-05	Ubicación Corea, República de	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03860272	TitleFc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer	Fase Fase 1	Date Added 2019-03-01	Ubicación Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Balstilimab, Botensilimab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05973487	TitleA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Fase Fase 1	Date Added 2023-08-03	Ubicación Arizona, United States California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05976906	TitleUniversal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors	Fase Fase 1	Date Added 2023-08-04	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05783089	TitleMSLN-targeted CAR-T Cells in Solid Tumors.	Fase Fase 1	Date Added 2023-03-24	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05785325	TitleRC48-ADC combinado con bevacizumab en cáncer colorrectal avanzado HER2-positivo	Fase Fase 2	Date Added 2023-03-27	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas RC48-ADC más Bevacizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05798533	TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)	Fase Fase 1	Date Added 2023-04-04	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Cyclophosphamide, Fludarabine, Interleukin-2	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05799443	TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer	Fase Fase 2	Date Added 2023-04-05	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas cetuximab, Irinotecan Hydrochloride, Tislelizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT00001823	TitleEvaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols	Fase	Date Added 1999-11-04	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05382741	TitleAdjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial	Fase Fase 2	Date Added 2022-05-19	Ubicación Italia	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga	Etiquetas MSS/ MMRp

Showing 121 to 130 of 299 entries